FDA Approves Revumenib for Relapsed or Refractory Acute Myeloid Leukaemia with a Susceptible NPM1 Mutation By Ogkologos - October 30, 2025 224 0 Facebook Twitter Google+ Pinterest WhatsApp Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Granting a Marketing Authorisation for Generic Palbociclib Metastasis-Directed Therapy for Oligometastatic Solid Tumours in Histology-Specific Context ctDNA Testing After Neoadjuvant Chemotherapy and Radical Cystectomy Predicts Recurrence Risk in Patients with MIBC MOST POPULAR Imlunestrant Improves PFS Among Patients with ESR1-mutated ER-positive, HER2-negative ABC and... December 17, 2024 InflaMix Identifies CAR-T Recipients with a Preinfusion Inflammatory Profile Indicative of... May 5, 2025 Experts Urge to Remove Care Inequalities for Adolescents and Young Adults... April 8, 2021 Great Oaks Grow From Small Acorns Oncology Is Committed to Doing... September 9, 2022 Load more HOT NEWS 8-Year-Old Cancer Survivor Celebrates Recovery By Donating Her Birthday Gifts To... PET-2-Guided BrECADD Better Tolerated and More Effective than eBEACOPP in Patients... Glucose Control Key in Reducing Cancer Risk for People with Type... 9/11 Firefighter Dies Of Cancer From Working At Ground Zero
